You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
NEW YORK (GenomeWeb News) – Indian biotech firm Sisco Research Laboratories announced today the purchase of Madras Biotech for an undisclosed amount.
NEW YORK (GenomeWeb News) – NeoProteomics announced on Tuesday it has been awarded a two-year, $300,000 grant from the National Institutes of Health to develop software for commercial applications.
The researchers will use an NIH grant to seek protein biomarkers in the blood to predict clinical outcomes of traumatic brain injury.
For its part in the project called DENAMIC, Proteome Sciences will investigate the effects of neurotoxic chemicals on proteins, peptides, and biochemical pathways in cell models and tissue.
The European patent covers IgY immunodepletion technology. Sigma-Aldrich has a final opportunity to argue its position in September.
Scienion will produce protein microarray batches of more than 1,000 arrays for Protagen for the clinical validation of biomarker panels.
Under the terms of an agreement, Protagen's UNIarray platform will be used to retrospectively analyze samples from a Biogen clinical trial in order to find predictive and response biomarkers in relapsing remitting MS.
The firms will co-develop a new tissue-based imaging and analysis solutions for protein biomarkers.
Pronota will use its MASStermind platform for the discovery stage of the deal, and its MASSterclass technology for the verification work.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.
According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.
CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.
In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.